Tetrastatin, a 230 amino acid sequence from collagen IV, was previously demonstrated to inhibit melanoma progression. In the present paper, we identified the minimal active sequence (QKISRCQVCVKYS: QS-13) that reproduced the anti-tumor effects of whole Tetrastatin in vivo and in vitro on melanoma cell proliferation, migration and invasion. We demonstrated that QS-13 binds to SK-MEL-28 melanoma cells through the αβ integrin using blocking antibody and β3 integrin subunit siRNAs strategies. Relevant QS-13 conformations were extracted from molecular dynamics simulations and their interactions with αβ integrin were analyzed by docking experiments to determine the binding areas and the QS-13 amino acids crucial for the binding. The in silico results were confirmed by in vitro experiments. Indeed, QS-13 binding to SK-MEL-28 was dependent on the presence of a disulfide-bound as shown by mass spectroscopy and the binding site on αβ was located in close vicinity to the RGD binding site. QS-13 binding inhibits the FAK/PIK/Akt pathway, a transduction pathway that is largely involved in tumor cell proliferation and migration. Taken together, our results demonstrate that the QS-13 peptide binds αβ integrin in a conformation-dependent manner and is a potent antitumor agent that could target cancer cells through αβ.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026150PMC
http://dx.doi.org/10.1038/s41598-018-28003-xDOI Listing

Publication Analysis

Top Keywords

αβ integrin
16
melanoma progression
8
fak/pik/akt pathway
8
cell proliferation
8
proliferation migration
8
cells αβ
8
qs-13 binding
8
binding site
8
qs-13
7
αβ
6

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!